TIANFU-CHEM 302962-49-8 Dasatinib CAS NO.302962-49-8

Min.Order Quantity:: 1 Kilogram

Purity:: 99%min

Port:: any port in china

Payment Terms:: L/C,T/T,

Add to Inquiry Cart

Product Details

Keywords

302962-49-8
Dasatinib
C22H28ClN7O3S

Quick Details

ProName: TIANFU-CHEM 302962-49-8 Dasatinib
CasNo: 302962-49-8
Molecular Formula: C22H28ClN7O3S
Appearance: conform
Application: 302962-49-8
DeliveryTime: within 7 days after PO
PackAge: normal package
Port: any port in china
ProductionCapacity: 1 Metric Ton/Day
Purity: 99%min
Storage: conform
Transportation: by air
LimitNum: 1 Kilogram
Grade: Industrial Grade,Food Grade,Pharma Gra...

Superiority

our company was built in 2009 with an iso certificate.in the past 5 years, we have grown up as a famous fine chemicals supplier in china and we had established stable business relationships with samsung,lg,merck,thermo fisher scientific and so on.our main business covers the fields below:

1.noble metal catalysts (pt.pd...)

2.organic phosphine ligands (tert-butyl-phosphine.cyclohexyl-phosphine...)

3.oled intermediates (fluorene,carbazole,boric acid...)

4.customs synthesis

our advantage:

1. higest quality and good package

2.fast delivery

3.better payment term

4.fast response to customer within 6 hours

5.good business credit in europe ,us ,japan ,korea

anyway ,if you need any chemicals from china ,henan tianfu can help you

Details

dasatinib basic information

leukemia drug chemical properties application

product name:	dasatinib
synonyms:	dasatinib(bms-354825);bms-354825;n-[2-chloro-6-methylphenyl]-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamide;5-thiazolecarboxamide, n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-;dasatinib;n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-1,3-thiazole-5-carboxamide;n-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide;2-{6-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-2-methyl-pyrimidin-4-ylamino}-thiazole-5-carboxylic acid (2-chloro-6-methyl-phenyl)-amide
cas:	302962-49-8
mf:	c22h28cln7o3s
mw:	488.01
einecs:
product categories:	intermediates & fine chemicals;pharmaceuticals;tyrosine kinase inhibitors;pharmaceutical intermediate;inhibitor;sprycel;anti-cancer&immunity;inhibitors
mol file:	302962-49-8.mol

dasatinib chemical properties

mp	275-286°c
storage temp.	-20°c freezer
cas database reference	302962-49-8(cas database reference)

safety information

msds information

dasatinib usage and synthesis

leukemia drug	dasatinib is an oral potent oncogenic kinase inhibitor, which can block signal of cancer cell replication acceleration , in may 2009, the us food and drug administration (fda) formally approved the sale of dasatinib , it has been clinically used for the treatment of various chronic myeloid leukemia (cml), including treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate., philadelphia chromosome-positive acute lymphoblastic leukemia (ph + all) and the treatment of patients with solid tumors. october 28, 2010 ,the fda approved dasatinib (sprycel) of the new indication which is used for the treatment of the rare leukemia first diagnosed philadelphia chromosome-positive called chronic myeloid leukemia (ph + cp-cml) . the disease is a blood and bone marrow disease associated with genetic abnormality . an open-label randomized clinical trial conducted in patients with cp-cml evaluated the safety and efficacy of dasatinib . common side effects include decreased activity of the bone marrow caused by red blood cells, white blood cells and platelets decreased (myelosuppression), fluid retention, diarrhea, headache, musculoskeletal pain, and rash. october 11, 2011, the us food and drug administration (fda) said the leukemia drug dasatinib (sprycel, bristol-myers squibb company) might increase pulmonary arterial hypertension (pah) risk. pulmonary hypertension is a rare but serious disease that can lead to the condition that heart pumping blood to the lungs becomes more difficult by raising the pressure . pah symptoms include shortness of breath, fatigue, swelling of the legs and ankles, clinicians must differentiate these symptoms from other similar symptoms. since 2006 dasatinib was approved in the us market ,there had been 12 associated pulmonary hypertension events ,pulmonary hypertension symptoms included shortness of breath, fatigue, hypoxia and fluid retention, patients then were confirmed pulmonary hypertension by the results of right heart catheterization ,studies have shown that the biggest cause of the disease may come from patients taking dasatinib. the above information is edited by the chemicalbook of tian ye.
chemical properties	white solid
application	suitable for treatment of chronic myeloid leukemia which is resistant or intolerant to the treating programs including imatinib mesylate.
chemical properties	pale-yellow solid
usage	a new, oral, small-molecule tyrosine kinase inhibitor (tki) for the treatment of cml. antineoplastic
usage	dasatinib is a novel, potent and multi-targeted inhibitor that targets abl, src and c-kit, with ic50 of ＜1 nm, 0.8 nm and 79 nm, respectively.